2023 World Conference on Lung Cancer (Posters)-EP12.01. Evaluation of the LITE-Risk Prognostic Model in Consolidation Durvalumab and Osimertinib-Treated NSCLC

EP12.01. Evaluation of the LITE-Risk Prognostic Model in Consolidation Durvalumab and Osimertinib-Treated NSCLC - PDF(Slides)

Back to course

Pdf Summary

This study evaluated the LITE-Risk prognostic model in two cohorts of non-small cell lung cancer (NSCLC) patients receiving different treatments. The LITE-Risk model is a simple risk stratification tool based on baseline characteristics routinely collected in standard care. The study aimed to determine if the LITE-Risk could differentiate outcomes in NSCLC patients treated with consolidation durvalumab or first-line osimertinib.<br /><br />The results showed that the LITE-Risk was not able to discriminate outcomes in durvalumab-treated patients, where the majority of patients had intermediate or favorable LITE-Risk scores. However, the LITE-Risk demonstrated prognostic ability in differentiating outcomes in osimertinib-treated advanced NSCLC patients. Patients with poor LITE-Risk scores had significantly shorter time to progression and reduced overall survival compared to those with intermediate or favorable LITE-Risk scores.<br /><br />The study also found that osimertinib-treated patients were different from durvalumab-treated patients in terms of clinical and demographic factors, such as disease stage and genetic mutations. The LITE-Risk was able to differentiate outcomes in osimertinib-treated patients, but not in durvalumab-treated patients.<br /><br />Overall, the LITE-Risk model showed promise as a prognostic tool for advanced NSCLC patients receiving systemic treatments, particularly in the metastatic setting. Further research and validation are needed to explore the utility of the LITE-Risk in other advanced NSCLC cohorts.<br /><br />This study was funded by a donation to the Glans-Look Lung Cancer Database, a real-world outcomes registry for NSCLC patients in Alberta, Canada. The authors concluded that the LITE-Risk, being simple, readily-accessible, and treatment-agnostic, could be beneficial for clinical practice in the advanced NSCLC setting.

Asset Subtitle

Amanda Gibson

Meta Tag

Speaker Amanda Gibson

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

LITE-Risk

prognostic model

NSCLC

treatments

outcomes

time to progression

overall survival

clinical factors

metastatic setting

advanced NSCLC